SurvivorNet on MSN
What the new pirtobrutinib approval means for people with chronic lymphocytic leukemia & small lymphocytic lymphoma
The FDA approved pirtobrutinib in October 2026 for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL) who have not yet been treated and do not have a specific ...
Chronic lymphocytic leukemia (CLL) is a cancer that primarily affects older adults and usually progresses slowly. This often means that people may not need treatment for some time. There is no cure ...
Hosted on MSN
What is fixed-duration CLL treatment?
Not long ago, treatment for chronic lymphocytic leukemia (CLL) often meant needing chemotherapy or a targeted medication for the rest of your life, as long as you tolerated it and your doctor could ...
Pirtobrutinib, a highly selective, noncovalent Bruton’s tyrosine kinase inhibitor (BTKi), shows substantial improvements in progression-free survival over the chemotherapy regimen of bendamustine plus ...
Jaypirca showed higher overall response rates than Imbruvica in both treatment-naive and relapsed/refractory CLL/SLL populations. Progression-free survival trends favored Jaypirca, especially in ...
A retrospective single-center study of 75 treatment-naive CLL/SLL patients reports an 86.7% response rate with frontline ...
Results from the phase 3 BRUIN CLL-313 trial show that OS trended favorably for pirtobrutinib vs chemoimmunotherapy in this CLL and SLL population. Pirtobrutinib (Jaypirca) demonstrated a highly ...
Even when physicians prescribe guideline-preferred therapies, step therapy and prior authorization can delay or restrict access to CLL therapies. “Science has transformed what is possible for people ...
Computer modelling and patient samples reveal alternative survival signalling in CLL, potentially enabling earlier treatment ...
Immunoglobulin replacement therapy in CLL patients does not reduce serious infection risk, despite increased usage over 14 years. The study found higher infection rates during immunoglobulin therapy ...
Copiktra (duvelisib) is a type of cancer treatment for certain people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). CLL and SLL are slow-growing cancers that affect a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results